This is about Argenx, a company that uses llama antibodies to treat autoimmune diseases (where the body attacks itself). Fund manager Julia Angeles is bullish, saying its drug could become one of the best-selling ever in 5-7 years. Key holdings: Argenx (stock up, strong sales), UCB (competitor targeting same disease), J&J (another competitor).
Argenx is an immunology company founded in 2008, with a market capitalization of $30 billion and projected sales exceeding $1 billion. Its core breakthrough stems from leveraging the llama antibody system to develop antibody therapies for complex diseases. The report, hosted by Zack Fuss of Irenic C
Julia Angeles (Baillie Gifford Investment Manager) and Zack Fuss (Irenic Capital) jointly dissect Argenx — an immunology company founded in 2008, with a market cap of $30 billion and on the verge of surpassing $1 billion in sales. The core narrative: how Argenx leverages the unique biological properties of llama antibodies to bridge the gap from lab to commercialization in autoimmune diseases. Julia Angeles believes that based solely on the four most advanced programs already in clinical trials, Argenx could generate $7–8 billion in revenue within 5–7 years, making it one of the best-selling drugs in history — and this only scratches the surface of its platform's potential.
Julia Angeles believes that the uniqueness of the llama antibody system is the fundamental source of Argenx’s technological differentiation, but the company’s true moat lies in its full suite of engineering technologies layered on top of llama antibodies.
Julia Angeles points out that the most critical turning point in Argenx’s history was not a scientific breakthrough, but the introduction of a long-term US investor (Orbimed), which shifted the company’s mindset from “single-asset sale” to “platform-based independent company” strategy.
Julia Angeles believes that Argenx's commercial success stems from its "truly patient-centric" culture, which is reflected in every aspect from drug design and clinical trials to pricing negotiations, ultimately resulting in one of the most successful drug launches in biotech history.
Julia Angeles believes that Argenx currently has 13 clinical programs based on a single immune mechanism, and could expand to 30–40 programs within 5–10 years, with a single indication in the U.S. market alone representing 60,000 patients.
| Position | Analyst Stance | Key Data |
|---|---|---|
| Argenx | Bullish | Market cap of $30 billion; 2023 sales expected to exceed $1 billion; $400 million in revenue in the first year of its first drug's launch; the four most advanced projects alone could generate $7-8 billion in revenue within 5-7 years |
| Ablynx | Background mention (acquired by Sanofi) | Also a Belgian alpaca antibody company |
| UCB | Competitive mention | Targeting the same target |
| J&J | Competitive mention | Targeting the same target |
| Novo Nordisk | Industry reference | Operating profit margin of 30-40% |
1. "With just four clinical-stage programs, Argenx could become one of the best-selling drugs in history within 5-7 years." (Julia Angeles) — Support: 60,000 patients each in the US and Europe × negotiated pricing, these four programs alone could generate $7-8 billion in revenue, and the company has 9 other clinical programs and numerous undisclosed indications.
2. "Argenx's biggest risk is not technical failure, but cultural dilution." (Julia Angeles) — Support: As the company transitions from a research-driven to a commercial organization, the commercial division may become too powerful, leading decisions driven by short-term revenue rather than long-term science.
3. "In the autoimmune space, competition between companies is not the main issue; the greater competition is changing standard of care and physicians' mindsets." (Julia Angeles) — Support: The field has seen no true innovation in 30 years, with existing therapies (e.g., intravenous immunoglobulin) requiring over 8 hours of infusion and causing severe side effects.
4. "Argenx's clinical trials not only collect data required by regulators but also gather real-world data on patients' quality of life — this helped them secure excellent pricing in negotiations with payers." (Julia Angeles) — Support: The launch of its first drug became one of the most successful launches in biotech history.
5. "The probability of approval for Argenx's pipeline drugs is not the industry average of 10%, but 60-70%." (Julia Angeles) — Support: Because the company truly understands the underlying biology it targets and its connection to disease, which fundamentally changes the economics of the business.
6. "Argenx's success is not about cool technology, but about people — the people executing that technology." (Julia Angeles) — Support: The company deliberately built a long-term shareholder base (e.g., Baillie Gifford invested $200 million in the first round and continued to add), ensuring scientific progress is not sacrificed for short-term capital pressure.
7. "Argenx began building its commercial team during Phase 2 clinical trials, while most companies wait until Phase 3 results are out — by then, it's already too late." (Julia Angeles) — Support: Early physician education and sales team building are key to a successful launch.
8. "If you walk into an Argenx project team, you can't tell who is a company employee and who is an external academic — this deep collaboration culture is something large pharma cannot replicate." (Julia Angeles) — Support: Collaborations with academic institutions are not transactional but genuine joint exploration, with the company granting scholars full experimental freedom and data sharing.